Gyre Therapeutics (GYRE) Minority Interest (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Minority Interest data on file, last reported at $35.7 million in Q1 2026.

• Minority Interest for Q1 2026 came in at $35.7 million, down 1.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.7 million (down 1.39% YoY), and the FY2025 annual result was $36.3 million, up 3.33% from the prior year.
• Minority Interest eased to $35.7 million in Q1 2026 per GYRE's latest filing, from $36.3 million in the prior quarter.
• Over five years, Minority Interest peaked at $37.4 million in Q2 2025 and troughed at $29.7 million in Q4 2022.
• A 5-year average of $34.2 million and a median of $35.3 million in 2024 frame the typical range for Minority Interest.
• The sharpest annual moves came in 2024 and 2026: Minority Interest climbed 17.82% in 2024, then declined 1.39% in 2026.
• A 5-year view of Minority Interest shows it stood at $29.7 million in 2022, then gained by 0.28% to $29.8 million in 2023, then advanced by 17.82% to $35.1 million in 2024, then climbed by 3.33% to $36.3 million in 2025, then dropped by 1.59% to $35.7 million in 2026.
• Business Quant data shows GYRE's Minority Interest at $35.7 million in Q1 2026, $36.3 million in Q4 2025, and $35.5 million in Q3 2025.